Compare BIO-TECHNE Corp (TECH) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs ProShares UltraPro QQQ ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while ProShares UltraPro QQQ ETF trades at $73.61. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while ProShares UltraPro QQQ ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| TECH | TQQQ | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.29 | $87.22 |
52-Week Low | $43.31 | $37.89 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
TQQQ, the ProShares UltraPro QQQ ETF, trades at $74.47, up 3.39% on the day, reflecting strong bullish momentum in the Nasdaq-100 index. Technical indicators show a bullish trend with moving averages supporting upward movement, though the RSI suggests potential overbought conditions. Recent news highlights TQQQ's significant gains driven by AI and tech sector strength, but also underscores risks from its 3x leverage and daily compounding costs.
The outlook for TQQQ remains positive amid tech-driven growth, but investors face amplified volatility and decay risks. Opportunities exist for tactical gains in a bullish market, yet the leveraged structure demands careful risk management due to potential sharp downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
